Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

@article{Turnbull2003EffectsOD,
  title={Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials},
  author={Fiona M Turnbull},
  journal={The Lancet},
  year={2003},
  volume={362},
  pages={1527-1535}
}

Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 – effects of different classes of antihypertensive drugs in older and younger patients overview and meta-analysis

Most BP-lowering classes are equally effective in preventing risk of fatal and nonfatal cardiovascular events both in older and younger patients, whereas beta-blockers loose some of their effectiveness at an older age.

Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?

  • Michael A. Weber
  • Medicine
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension
  • 2009
It is established that telmisartan reduces morbidity and mortality in a broad cross-section of patients at high risk for heart and vascular events, to an extent similar to that of the angiotensin-converting enzyme inhibitor ramipril.

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.

These overviews showed that the short- to-medium-term effects on major cardiovascular events of the BP-lowering regimens studied were broadly comparable for patients with and without diabetes.

Dual blockade of the renin-angiotensin system: are two better than one?

  • R. HaynesP. MasonK. RahimiM. Landray
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2009
There is continuing uncertainty about the balance of benefits and harms of dual RAS blockade, both in terms of cardiovascular risk and progression of kidney disease.

The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials

The findings suggest that additional blood pressure reduction in hypertensive patients meeting initial blood pressure targets will produce further benefits, and the data are supportive of the utilization of blood pressure-lowering regimens in high-risk patients with and without hypertension.

Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.

In subjects with TRH, intensive lipid lowering with atorvastatin 80 mg is associated with a significant reduction in cardiovascular events, and results were similar when analysed for the two separate components of the TRH cohort.
...

References

SHOWING 1-10 OF 56 REFERENCES

Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.

The combination of trial results in prospectively planned, systematic overviews both reduces random errors and avoids biases and should provide more reliable information about the effects of newer blood-pressure-lowering drugs than would any one study alone.

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive and should be preferred for first-step antihypertensive therapy.

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

The data indicate that compared with doxazosin, chlorthalidone reduces the risk of combined CVD events, particularly CHD death/nonfatal MI, in high-risk hypertensive patients.

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

Initiation of antihypertensive treatment involving ACE inhibitors in older subjects, particularly men, appears to lead to better outcomes than treatment with diuretic agents, despite similar reductions of blood pressure.

Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack

This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and non-hypertensive individuals with a history of stroke or transient ischaemic attack, irrespective of their blood pressure.
...